+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 21Years - 65Years
All Genders
ID06759558

Evaluating Oral Zuranolone for Safety and Effectiveness in Adults With Moderate to Severe Post-Stroke Depression

Led by Duke University · Updated on 2026-09-03

6

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This Phase II clinical trial is studying adults aged 21 to 65 who have moderate to severe depression following a stroke. Researchers aim to find out if the oral synthetic allopregnanolone analog called zuranolone is safe and well tolerated by stroke survivors with post-stroke depression and whether it helps improve depression symptoms. The study focuses on treating depression that has lasted at least two weeks with a high score on the Hamilton Depression Rating Scale. Participants will receive 50 mg of zuranolone once daily for 14 days. This medication acts on the brains GABA receptors and is given as a pill. The trial includes only one group receiving zuranolone. During the study, participants will provide blood samples and complete mood questionnaires as well as cognitive tests. Throughout the 90-day follow-up, researchers will monitor side effects like adverse events, suicidal thoughts, and sleepiness. They will also measure changes in depression and anxiety scores at several time points including days 3, 15, and 90. The study involves regular assessments to track safety and mood improvements after treatment with zuranolone.

CONDITIONS

Brief Title

Allopregnanolone (Zuranolone) in Post-stroke Depression

Research Team

S

Sheila Joshi

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here